– USA, CA – Nine Square Therapeutics, a biotechnology company announced the appointment of Dr. James Summers (Ph.D.) to its board of directors and its scientific advisory board.
About Dr. James B. Summers
During more than 30 years with Abbott and AbbVie, Dr. Summers held various senior R&D leadership positions, including vice president of neuroscience research, where he led efforts located in Ludwigshafen, Germany, Lake County, IL and Cambridge, MA, focused on the discovery of new drugs for the treatment of Alzheimer’s and Parkinson’s diseases, pain and psychiatric disorders. Under his leadership, the teams advanced more than 20 compounds into clinical development. Currently Dr. Summers serves as a board member and advisor to several biotechnology companies. He is also a venture partner with the Dementia Discovery Fund. Dr. Summers earned a Bachelor of Science in Chemistry, summa cum laude, from Denison University and a Doctorate in Organic Chemistry from Harvard University.
“Boosting autophagy to address genetically validated but previously undruggable targets presents an incredibly exciting opportunity to address the longstanding challenges of treating severe neurodegenerative diseases,” said Dr. James Summers. “I am pleased to join this esteemed interdisciplinary team of scientists and biotech leaders at Nine Square. Together, we will advance our programs towards IND-enabling studies and into clinical development, offering new hope for patients and the neuroscience community.”
About Nine Square Therapeutics
Nine Square Therapeutics is a biotechnology company integrating phenotypic cell profiling, chemistry and computational sciences in a quest to alter the trajectory of neurodegenerative disease. Founded by life sciences venture capital firm Apple Tree Partners and renowned scientists at the University of California San Francisco, Nine Square’s goal is to discover better drugs, faster. The company’s platform is currently focused on boosting autophagy/mitophagy, the body’s own cellular degrading machinery, with programs initially focused on Parkinson’s disease, amyotrophic lateral sclerosis and lysosomal storage diseases.
For more information : https://www.ninesquaretx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.